Retina (Philadelphia, Pa.) · 2026
MODELING NATURAL HISTORY AND COST-EFFECTIVENESS OF GENE-AGNOSTIC TREATMENT IN RETINITIS PIGMENTOSA.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sullivan Patrick W, Wertheimer Albert I, Grover Sandeep, Jayasundera Kanishka T
Аннотация
PURPOSE: Treatment options for retinitis pigmentosa (RP) have been limited. A new generation of innovative but potentially expensive treatments under development may halt or reverse disease progression.
METHODS: Using an existing database, a closed-cohort microsimulation model of all genetic subtypes of RP was conducted from a U.S. societal perspective. A hypothetical gene-agnostic therapy was compared with standard care at age 30. Outcomes included VF and VA progression; incremental cost-effectiveness ratio (ICER: dollars per quality-adjusted life-year (QALY) gained); and lifetime medical and productivity-related costs.
RESULTS: Baseline cohort (age 30, N = 381; mean VA logMAR, 0.26 (20/36); mean VF sum total degrees (III4e), 749). By age 45, 79% of patients with untreated RP reached legal blindness or worse, compared with significantly delayed progression with treatment. ICER of gene-agnostic therapy was $158,554/QALY, yielding better outcomes compared with untreated RP (20.5 vs. 16.7 QALYs) and substantial indirect cost savings ($691,961) if a drug price of $1.5 million was assumed.
CONCLUSION: A gene-agnostic treatment for RP with drug price of $1.5 million (both eyes) may be cost-effective for most types of RP, particularly with earlier initiation. These findings can inform clinical, economic, and health policy decisions, potentially supporting early intervention strategies and resource allocation for novel RP treatments.
METHODS: Using an existing database, a closed-cohort microsimulation model of all genetic subtypes of RP was conducted from a U.S. societal perspective. A hypothetical gene-agnostic therapy was compared with standard care at age 30. Outcomes included VF and VA progression; incremental cost-effectiveness ratio (ICER: dollars per quality-adjusted life-year (QALY) gained); and lifetime medical and productivity-related costs.
RESULTS: Baseline cohort (age 30, N = 381; mean VA logMAR, 0.26 (20/36); mean VF sum total degrees (III4e), 749). By age 45, 79% of patients with untreated RP reached legal blindness or worse, compared with significantly delayed progression with treatment. ICER of gene-agnostic therapy was $158,554/QALY, yielding better outcomes compared with untreated RP (20.5 vs. 16.7 QALYs) and substantial indirect cost savings ($691,961) if a drug price of $1.5 million was assumed.
CONCLUSION: A gene-agnostic treatment for RP with drug price of $1.5 million (both eyes) may be cost-effective for most types of RP, particularly with earlier initiation. These findings can inform clinical, economic, and health policy decisions, potentially supporting early intervention strategies and resource allocation for novel RP treatments.